A clinical study published in the New England Journal of Medicine in 2024 (4) showed that, in people with excess fatty liver with mild to moderate fibrosis , administration of drugs once a week for 240 weeks was correlated with: improvement in liver composition and inflammation without worsening of fibrosis in more than 60% of cases, compared with approximately 34% of subjects on placebo reduction in scar tissue without worsening of steatohepatitis in more than 36% of patients, compared with around 22% of those on placebo resolution of steatohepatitis with a reduction in fibrosis in 32.7% of patients, compared with 16.1% in the placebo group average reduction in body weight of 10.5%, compared with just 2.0% on placebo The mechanisms that could explain these results From a medical point of view, these effects on liver health could be explained by several complementary mechanisms: a general reduction in body fat , particularly visceral fat in the abdomen and liver, a criterion often associated with improvements in liver parameters (5) a reduction in oxidative stress , known to damage liver cells (6) Although potentially interesting for supporting liver function , GLP-1 agonists are drug treatments that can have side effects (7)
Selection of DCM/ethanol system for the nanoprecipitation method was based on an evaluation of the suspendablity of DDA-GSH-AuNCs after phase transfer in various solvents that include good and poor solvents for PLGA as detailed in Fig
Milk and fermented dairy products, which are not considered rich in folate, constitute an important dietary source of folate because they are consumed in relatively large quantities
In one case, a man who ate mostly canned beef developed scurvy twice
